Ewha Med J.  2024 Jul;47(3):e36. 10.12771/emj.2024.e36.

The epidemiology of HIV/AIDS and the use of antiretroviral therapy in Korea: a narrative review

• Ku NS

• KMID: 2558573
• DOI: http://doi.org/10.12771/emj.2024.e36

Abstract

The availability of combined antiretroviral therapy has significantly reduced the number of new HIV infections and the associated mortality, and HIV infection has become a chronic disease with longterm survival. In Korea, more than 1,000 new HIV infections have been registered annually since 2013. After peaking at 1,223 in 2019, the number of new infections decreased between 2020 and 2023. In 2023, the majority of newly HIV-infected people were men, and the proportions of young people under 40 years, homosexual contacts and foreigners increased. Acquired immunodeficiency syndrome (AIDS)-related deaths from opportunistic infections associated with immunosuppression and AIDS-defining cancers are gradually decreasing, whereas non-AIDS defining comorbidities such as non-AIDS defining cancers, cardiovascular disease and metabolic complications are emerging as major causes of death. Since the introduction of zidovudine, approximately 30 antiretroviral drugs have been approved for the treatment of HIV infection. Early and continuous antiretroviral treatment for all people living with HIV is an effective strategy for maintaining viral suppression and preventing transmission of HIV infection. In conclusion, achieving the 95–95–95 target among those living with HIV in Korea requires multifaceted efforts to improve early diagnosis, early and proper treatment of HIV infection including the management of chronic diseases, and adherence to antiretroviral therapy.

Keyword

Antiretroviral therapy; HIV; Non-AIDSdefining comorbidities

Figure

• 

  Fig. 1. New human immunodeficiency virus infections in Korea according to year. Adapted from Korea Centers for Disease Control and Prevention [10] with CC-BY.

Reference

References

1. Joint United Nations Programme on HIV/AIDS. The path that ends AIDS: 2023 UNAIDS global AIDS update [Internet]. Geneva (CH): Joint United Nations Programme on HIV/AIDS. c2023. [cited 2024 Jan 13]. Available from: https://www.unaids.org/en/resources/documents/2023/global-aids-update-2023.

2. Joint United Nations Programme on HIV/AIDS. 90-90-90: an ambitious treatment target to help end the AIDS epidemic [Internet]. Geneva (CH): Joint United Nations Programme on HIV/AIDS;c2024. [cited 2024 Jan 13]. Available from: https://www.unaids.org/en/resources/909090.

3. Frescura L, Godfrey-Faussett P, Ali Feizzadeh A, El-Sadr W, Syarif O, Ghys PD, et al. Achieving the 95 95 95 targets for all: a pathway to ending AIDS. PLoS One. 2022; 17(8):e0272405. DOI: 10.1371/journal.pone.0272405. PMID: 35925943. PMCID: PMC9352102.

4. Korea Centers for Disease Control and Prevention. 2^nd Strategies for the preventive management of HIV/AIDS (2024-2028). Cheongju: Korea Centers for Disease Control and Prevention;2024.

5. Youn BB, Kang HC, Oh YW, Lee CH. A case report of an acquired immunodeficiency syndrome with multiple problems, such as fever, dyspnea, abdominal pain, oral candidiasis candida albicans esophagitis, etc. N Med J. 1985; 28:63–72.

6. Korea Centers for Disease Control and Prevention. Annual report on the notified HIV/AIDS in Korea, 2010. Cheongju: Korea Centers for Disease Control and Prevention;2011.

7. Korea Centers for Disease Control and Prevention. Annual report on the notified HIV/AIDS in Korea, 2022. Cheongju: Korea Centers for Disease Control and Prevention;2023.

8. Kim JM, Kim NJ, Choi JY, Chin BS. History of acquired immune deficiency syndrome in Korea. Infect Chemother. 2020; 52(2):234–244. DOI: 10.3947/ic.2020.52.2.234. PMID: 32618149. PMCID: PMC7335645.

9. Kim GS, Kim L, Baek S, Shim MS, Lee S, Kim JM, et al. Three cycles of mobile app design to improve HIV self-management: a development and evaluation study. Digit Health. 2024; 10:20552076241249294. DOI: 10.1177/20552076241249294. PMID: 38680735. PMCID: PMC11055484.

10. Korea Centers for Disease Control and Prevention. Annual report on the notified HIV/AIDS in Korea, 2023. Cheongju: Korea Centers for Disease Control and Prevention;2024.

11. Ann HW, Jun S, Shin NY, Han S, Ahn JY, Ahn MY, et al. Characteristics of resting-state functional connectivity in HIV-associated neurocognitive disorder. PLoS One. 2016; 11(4):e0153493. DOI: 10.1371/journal.pone.0153493. PMID: 27104345. PMCID: PMC4841538.

12. Yoo M, Seong J, Yoon JG, Cha J, Chung YS, Kim K, et al. Characteristics of adolescents and young adults with HIV in the Republic of Korea from 2010 through 2015. Sci Rep. 2020; 10(1):9384. DOI: 10.1038/s41598-020-66314-0. PMID: 32523123. PMCID: PMC7287062.

13. Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005; 34(1):121–130. DOI: 10.1093/ije/dyh307. PMID: 15561752.

14. Park B, Choi Y, Kim JH, Seong H, Kim YJ, Lee M, et al. Mortality and causes of death among individuals diagnosed with human immunodeficiency virus in Korea, 2004–2018: an analysis of a nationwide population-based claims database. Int J Environ Res Public Health. 2022; 19(18):11788. DOI: 10.3390/ijerph191811788. PMID: 36142061. PMCID: PMC9517230.

15. Smit M, Brinkman K, Geerlings S, Smit C, Thyagarajan K, Sighem A, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015; 15(7):810–818. DOI: 10.1016/S1473-3099(15)00056-0. PMID: 26070969.

16. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet; 2014; 384(9939):241–248. DOI: 10.1016/S0140-6736(14)60604-8. PMID: 25042234.

17. Wong C, Gange SJ, Moore RD, Justice AC, Buchacz K, Abraham AG, et al. Multimorbidity among persons living with human immunodeficiency virus in the United States. Clin Infect Dis. 2018; 66(8):1230–1238. DOI: 10.1093/cid/cix998. PMID: 29149237. PMCID: PMC5889007.

18. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011; 53(11):1120–1126. DOI: 10.1093/cid/cir627. PMID: 21998278.

19. Hsu DC, Sereti I. Serious non-AIDS events: therapeutic targets of immune activation and chronic inflammation in HIV infection. Drugs. 2016; 76(5):533–549. DOI: 10.1007/s40265-016-0546-7. PMID: 26915027. PMCID: PMC5578711.

20. Kim J, Nam HJ, Jung YJ, Lee HJ, Kim SE, Kang SJ, et al. Weight gain and lipid profile changes in Koreans with human immunodeficiency virus undergoing integrase strand transfer inhibitor-based regimens. Infect Chemother. 2022; 54(3):419–432. DOI: 10.3947/ic.2022.0063. PMID: 35920267. PMCID: PMC9533166.

21. Kim JH, Noh J, Kim W, Seong H, Kim JH, Lee WJ, et al. Trends of age-related non-communicable diseases in people living with HIV and comparison with uninfected controls: a nationwide population-based study in South Korea. HIV Med. 2021; 22(9):824–833. DOI: 10.1111/hiv.13139. PMID: 34263511.

22. High KP, Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR FM, et al. Workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008; 47(4):542–553. DOI: 10.1086/590150. PMID: 18627268. PMCID: PMC3130308.

23. Okeke NL, Hicks CB, McKellar MS, Fowler VG Jr, Federspiel JJ. History of AIDS in HIV-infected patients is associated with higher in-hospital mortality following admission for acute myocardial infarction and stroke. J Infect Dis. 2016; 213(12):1955–1961. DOI: 10.1093/infdis/jiw082. PMID: 26941281. PMCID: PMC4878727.

24. Jung H, Lee E, Ro J, Lee JY, Bang J. Mortality after acute coronary syndrome in human immunodeficiency virus infection with optimal adherence: a nationwide study. Infect Chemother. 2023; 55(4):471–478. DOI: 10.3947/ic.2023.0050. PMID: 38014728. PMCID: PMC10771943.

25. Bae JY, Kim SM, Choi Y, Choi JY, Kim SI, Kim SW, et al. Comparison of three cardiovascular risk scores among HIV-infected patients in Korea: the Korea HIV/AIDS cohort study. Infect Chemother. 2022; 54(3):409–418. DOI: 10.3947/ic.2022.0048. PMID: 35920266. PMCID: PMC9533153.

26. Kalra S, Kalra B, Agrawal N, Unnikrishnan AG. Understanding diabetes in patients with HIV/AIDS. Diabetol Metab Syndr. 2011; 3(1):2. DOI: 10.1186/1758-5996-3-2. PMID: 21232158. PMCID: PMC3025836.

27. Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020; 71(6):1379–1389. DOI: 10.1093/cid/ciz999. PMID: 31606734. PMCID: PMC7486849.

28. Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief report: weight gain in persons with HIV switched from efavirenz-based to integrase strand transfer inhibitor-based regimens. J Acquir Immune Defic Syndr. 2017; 76(5):527–531. DOI: 10.1097/QAI.0000000000001525. PMID: 28825943. PMCID: PMC5680113.

29. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006; 20(17):2165–2174. DOI: 10.1097/QAD.0b013e32801022eb. PMID: 17086056.

30. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008; 93(9):3499–3504. DOI: 10.1210/jc.2008-0828. PMID: 18593764. PMCID: PMC2567857.

31. Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010; 24(18):2827–2833. DOI: 10.1097/QAD.0b013e328340a28d. PMID: 21045635.

32. Hong N, Kim JH, Treece G, Kim HC, Choi JY, Rhee Y. Cortical and trabecular bone deficit in middle‐aged men living with HIV. J Bone Miner Res. 2023; 38(9):1288–1295. DOI: 10.1002/jbmr.4873. PMID: 37358254.

33. Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59(9):e96–e138. DOI: 10.1093/cid/ciu617. PMID: 25234519. PMCID: PMC4271038.

34. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health. 2012; 12:234. DOI: 10.1186/1471-2458-12-234. PMID: 22439731. PMCID: PMC3402981.

35. Kim JH, Jang H, Kim JH, Song JY, Kim SW, Kim SI, et al. The incidence and risk factors of renal insufficiency among Korean HIV infected patients: the Korea HIV/AIDS cohort study. Infect Chemother. 2022; 54(3):534–541. DOI: 10.3947/ic.2022.0101. PMID: 36196611. PMCID: PMC9533162.

36. Kim K, Jang S, Rim HD, Kim SW, Chang H, Woo J. Attachment insecurity and stigma as predictors of depression and anxiety in people living with HIV. Psychiatry Investig. 2023; 20(5):418–429. DOI: 10.30773/pi.2022.0271. PMID: 37253467. PMCID: PMC10232058.

37. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr. 2011; 58(2):181–187. DOI: 10.1097/QAI.0B013E31822D490A. PMID: 21857529. PMCID: PMC3858003.

38. Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012; 80(3):404–415. DOI: 10.1037/a0028208. PMID: 22545737. PMCID: PMC3365619.

39. Kim JH, Kim JM, Ye M, Lee JI, Na S, Lee Y, et al. Implementation of a nurse-delivered cognitive behavioral therapy for adherence and depression of people living with HIV in Korea. Infect Chemother. 2022; 54:733–743. DOI: 10.3947/ic.2022.0118. PMID: 36450289. PMCID: PMC9840965.

40. Zipursky AR, Gogolishvili D, Rueda S, Brunetta J, Carvalhal A, McCombe JA, et al. Evaluation of brief screening tools for neurocognitive impairment in HIV/AIDS: a systematic review of the literature. AIDS. 2013; 27(15):2385–2401. DOI: 10.1097/QAD.0b013e328363bf56. PMID: 23751261. PMCID: PMC3814629.

41. Ku NS, Lee Y, Ahn JY, Song JE, Kim MH, Kim SB, et al. HIV-associated neurocognitive disorder in HIV-infected Koreans: the Korean NeuroAIDS project. HIV Med. 2014; 15(8):470–477. DOI: 10.1111/hiv.12137. PMID: 24580888. PMCID: PMC4140963.

42. Lee SO, Lee JE, Lee S, Lee SH, Kang JS, Son H, et al. Nationwide population-based incidence of cancer among patients with HIV/AIDS in South Korea. Sci Rep. 2022; 12(1):9974. DOI: 10.1038/s41598-022-14170-5. PMID: 35705675. PMCID: PMC9200856.

43. Park B, Ahn KH, Choi Y, Kim JH, Seong H, Kim YJ, et al. Cancer incidence among adults with HIV in a population-based cohort in Korea. JAMA Netw Open. 2022; 5(8):e2224897. DOI: 10.1001/jamanetworkopen.2022.24897. PMID: 35917123. PMCID: PMC9346552.

44. Lee SO, Lee JE, Sim YK, Lee S, Ko WS, Kim J, et al. Changing trends in the incidence and spectrum of cancers between 1990 and 2021 among HIV-infected patients in Busan, Korea. J Infect Chemother. 2023; 29(6):571–575. DOI: 10.1016/j.jiac.2023.01.018. PMID: 36716862.

45. Lee CH, Lee SH, Lee S, Cho H, Kim KH, Lee JE, et al. Anal human papillomavirus infection among HIV-infected men in Korea. PLoS One. 2016; 11(8):e0161460. DOI: 10.1371/journal.pone.0161460. PMID: 27548632. PMCID: PMC4993367.

46. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987; 317(4):185–191. DOI: 10.1056/NEJM198707233170401. PMID: 3299089.

47. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997; 337(11):725–733. DOI: 10.1056/NEJM199709113371101. PMID: 9287227.

48. Clinicalinfo. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV [Internet]. Rockville (MD): Office of AIDS Research;c2023; [cited 2023 Nov 22]. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new.

49. Lee SH, Kim KH, Lee SG, Chen DH, Jung DS, Moon CS, et al. Trends of mortality and cause of death among HIV-infected patients in Korea, 1990-2011. J Korean Med Sci. 2013; 28(1):67–73. DOI: 10.3346/jkms.2013.28.1.67. PMID: 23341714. PMCID: PMC3546107.

50. Shin YH, Park CM, Yoon CH. An overview of human immunodeficiency virus-1 antiretroviral drugs: general principles and current status. Infect Chemother. 2021; 53(1):29–45. DOI: 10.3947/ic.2020.0100. PMID: 34409780. PMCID: PMC8032919.

51. Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020; 382(12):1112–1123. DOI: 10.1056/NEJMoa1904398. PMID: 32130809.

52. Kim MS, Shin SY, Park YS, Kim YA, Ku NS, Kim JH, et al. Therapeutic response of HAART and analysis of related factors in Korean HIV-infected persons. Infect Chemother. 2007; 39(3):142–150.

53. Kim MH, Song JE, Ahn JY, Kim YC, Oh DH, Choi H, et al. HIV antiretroviral resistance mutations among antiretroviral treatment-naive and -experienced patients in South Korea. AIDS Res Hum Retroviruses. 2013; 29(12):1617–1620. DOI: 10.1089/aid.2013.0184. PMID: 23952717. PMCID: PMC3848436.

54. Oh SM, Bang J, Park SW, Lee E. Resistance trends of antiretroviral agents in people with human immunodeficiency virus in Korea, 2012 - 2020. Infect Chemother. 2023; 55(3):328–336. DOI: 10.3947/ic.2022.0150. PMID: 37272233. PMCID: PMC10551708.